volume 16, issue 3-4, P1-12 2020
DOI: 10.1177/1747016120943730
View full text
|
|
Share

Abstract: It has been proposed that the urgency of having a vaccine as a response to SARS-CoV-2 is so great, given the potential health, economic and social benefits that we should override the established steps in the research development process. In this article I argue that whilst there are some opportunities to expedite the production of a vaccine, it is a mistake to rush the research. We should retain the existing structures represented by clear and separate ‘phasing’ of trials. I offer three reasons for this view…

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
2
0

Publication Types

Select...

Relationship

0
0

Authors

Journals